Mood Stabilizers (Lithium)

Introduction

Lithium has long been regarded as a cornerstone in the management of bipolar disorder, offering both acute and long‑term therapeutic benefits. As a monovalent ion, it exerts a broad spectrum of neurochemical effects that dampen manic episodes and reduce the risk of suicide. The use of lithium dates back to the late nineteenth century, when its mood‑stabilizing properties were first reported following accidental ingestion. Over subsequent decades, systematic investigations have clarified its mechanisms of action, pharmacokinetic profile, and therapeutic window, thereby establishing lithium as a uniquely effective pharmacologic agent for mood disorders.

In the context of pharmacology and clinical medicine, lithium occupies a special position. Unlike many other psychotropics, it demonstrates a direct correlation between serum concentration and clinical efficacy, yet it also presents a narrow therapeutic index that necessitates vigilant monitoring. Teaching about lithium offers students an opportunity to explore the interplay between basic science, clinical pharmacology, and patient safety, as well as to appreciate the historical evolution of psychiatric therapeutics.

Learning objectives for this chapter include:

• To describe the pharmacokinetic parameters and therapeutic monitoring requirements of lithium.
• To outline the principal pharmacodynamic mechanisms underlying lithium’s mood‑stabilizing action.
• To identify common adverse effects and potential drug interactions associated with lithium therapy.
• To apply evidence‑based principles in the management of patients receiving lithium.
• To evaluate clinical scenarios that illustrate the decision‑making process in lithium treatment.

Fundamental Principles

Core Concepts and Definitions

Lithium is a naturally occurring alkali metal that, in the form of lithium carbonate, lithium citrate, or lithium acetate, is administered orally. It is classified as a mood stabilizer due to its capacity to modulate affective cycles, particularly within bipolar disorder. The term “mood stabilizer” refers to agents that prevent or reduce the intensity of both manic and depressive episodes. Lithium’s therapeutic action is distinguished from that of anticonvulsants or antipsychotics, which may target specific symptom clusters but do not consistently stabilize mood across the full spectrum of affective states.

Theoretical Foundations

The therapeutic effect of lithium is believed to arise from its influence on intracellular signaling cascades. By inhibiting phosphoinositide hydrolysis and glycogen synthase kinase‑3β (GSK‑3β), lithium reduces the phosphorylation of downstream proteins that regulate neurotransmitter release and neuronal plasticity. Additionally, lithium modulates cyclic adenosine monophosphate (cAMP) levels, which in turn influences neuronal excitability and the expression of neurotrophic factors such as brain‑derived neurotrophic factor (BDNF). The integration of these pathways is thought to underlie lithium’s capacity to dampen hyperexcitability during mania and to promote resilience against depressive relapse.

Key Terminology

• Therapeutic window – The serum concentration range within which lithium exerts clinical benefit while minimizing toxicity.
• Serum lithium concentration (SLC) – The measured amount of lithium in the bloodstream, typically expressed in millimoles per liter (mmol/L).
• Clearance (Cl) – The volume of plasma from which lithium is completely removed per unit time, reflecting renal excretion.
• Half‑life (t½) – The time required for the serum lithium concentration to decrease by 50 % under steady‑state conditions.
• Renal tubular reabsorption – The process by which lithium is reabsorbed in the proximal tubule, an event that parallels sodium handling.
• Neuroprotection – Protective effects on neuronal structure and function, a property attributed to lithium’s modulation of neurotrophic signaling.

Detailed Explanation

Pharmacokinetics

Lithium is well absorbed from the gastrointestinal tract, with an oral bioavailability approaching 100 %. Peak plasma levels are typically reached within 1–2 hours of ingestion. The distribution of lithium is extensive; it equilibrates rapidly between plasma and extracellular fluid compartments, with a volume of distribution approximating body water (≈0.9 L/kg). The central nervous system receives a substantial proportion of circulating lithium, as the ion crosses the blood–brain barrier via passive diffusion.

Elimination of lithium occurs almost exclusively through the kidneys, where it is filtered freely by the glomerulus and subsequently reabsorbed in the proximal tubule. The reabsorption rate parallels sodium handling, rendering lithium clearance sensitive to variations in sodium intake and renal perfusion. In healthy adults, the mean half‑life of lithium is approximately 18–24 hours, though this duration can increase markedly in patients with impaired renal function or dehydration.

The steady‑state serum concentration (Css) can be estimated using the following relationship:

• Css = (dose rate / Clearance)

Because clearance is predominantly renal, it is strongly influenced by glomerular filtration rate (GFR). Consequently, any factor that reduces GFR—such as dehydration, concomitant nephrotoxic agents, or concomitant use of angiotensin‑converting enzyme inhibitors—can elevate serum lithium levels. Conversely, increased sodium intake, hypernatremia, or diuretic use that enhances sodium excretion can augment lithium clearance, potentially lowering serum concentrations below therapeutic thresholds.

Pharmacodynamics

Multiple molecular targets have been implicated in lithium’s therapeutic action, and these targets converge upon modulation of neuronal excitability and synaptic plasticity. The principal mechanisms include:

• Inhibition of phosphatidylinositol 3‑kinase (PI3K) pathway – Lithium reduces the activity of phospholipase C, thereby decreasing the production of inositol triphosphate (IP3) and the subsequent release of intracellular calcium.
• Suppression of GSK‑3β – By inhibiting this kinase, lithium promotes the transcription of genes involved in neuronal survival and reduces the phosphorylation of tau protein.
• Modulation of cAMP signaling – Lithium dampens adenylyl cyclase activity, leading to decreased cAMP levels and altered protein kinase A (PKA) signaling.
• Alteration of neurotransmitter release – Through its effects on intracellular calcium dynamics, lithium can attenuate the release of glutamate and norepinephrine while enhancing serotonergic tone.
• Neurotrophic support – Lithium upregulates BDNF expression, which supports neuronal growth and resilience.

These pharmacodynamic actions collectively reduce hyperexcitability during manic episodes, stabilize mood fluctuations, and provide neuroprotection that may underlie lithium’s anti‑suicidal effects.

Therapeutic Drug Monitoring and Dose Calculation

Because lithium’s therapeutic range is narrow, regular serum monitoring is mandatory. Typical target concentrations are 0.6–1.0 mmol/L for acute mania and 0.4–0.8 mmol/L for maintenance therapy. Dosing regimens are individualized, taking into account age, renal function, weight, and comorbidities. An initial low dose (e.g., 300 mg twice daily) is often used to mitigate the risk of toxicity, with gradual titration over several weeks. The use of a loading dose (e.g., 300–600 mg/kg) may be considered in severe mania, provided close monitoring is ensured.

In patients with reduced renal function, dose adjustments are necessary to maintain serum levels within the therapeutic window. For example, a patient with a GFR of 30 mL/min may require a reduction of the maintenance dose by 30–50 %. Dose adjustments should be guided by the most recent serum lithium concentration and clinical response.

Factors Influencing Lithium Levels

• Renal function – Decreased glomerular filtration leads to accumulation of lithium.
• Hydration status – Dehydration increases serum lithium concentration due to reduced plasma volume.
• Dietary sodium – High sodium intake promotes lithium reabsorption, raising serum levels; conversely, sodium restriction enhances lithium excretion.
• Concurrent medications – Angiotensin‑converting enzyme inhibitors, non‑steroidal anti‑inflammatory drugs, and diuretics can alter lithium clearance.
• Age – Elderly patients often exhibit reduced renal function and increased sensitivity to lithium.
• Genetic factors – Polymorphisms in genes encoding renal transporters may affect lithium handling.

Clinical Significance

Relevance to Drug Therapy

Lithium’s efficacy in treating bipolar disorder, particularly in reducing manic episodes and preventing depressive relapse, has been documented in numerous controlled trials. It remains the most effective agent for suicide prevention among psychiatric drugs. In clinical practice, lithium is often chosen as a first‑line mood stabilizer, especially in patients with a history of rapid cycling or severe mania. Its use is complemented by other pharmacologic agents—such as anticonvulsants or atypical antipsychotics—when monotherapy is insufficient.

Practical Applications

In routine care, lithium is typically initiated at a low dose and titrated to achieve target serum concentrations. Patients are counselled to maintain consistent sodium intake and adequate hydration to avoid fluctuations in lithium levels. Regular follow‑up visits are scheduled to monitor renal function, thyroid function, and serum lithium concentration. When serum lithium falls below the therapeutic range, dose adjustments are made; conversely, if toxicity is suspected, the dose is reduced or discontinued pending laboratory confirmation.

Clinical Examples

Consider a 35‑year‑old man presenting with a manic episode characterized by grandiosity, pressured speech, and impaired sleep. After initiating lithium carbonate at 300 mg twice daily, serum lithium levels are measured after 1 week, revealing 0.7 mmol/L. The patient reports improvement in mood and no adverse effects. Over the next 6 months, the serum level remains within 0.6–0.8 mmol/L, and the patient experiences no further manic or depressive episodes. This case illustrates the successful use of lithium as both acute and maintenance therapy, highlighting the importance of therapeutic drug monitoring.

Clinical Applications/Examples

Case Scenarios

1. Scenario A: Rapid‑Cycling Bipolar Disorder in an Elderly Patient
   A 68‑year‑old woman with a history of rapid‑cycling bipolar disorder presents for management. Her serum creatinine is 1.8 mg/dL (estimated GFR ≈ 45 mL/min). Lithium is initiated at 150 mg twice daily, with serum lithium checked after 2 weeks. The concentration is 0.5 mmol/L, indicating a subtherapeutic level. The dose is increased to 300 mg twice daily, and the next level is 0.8 mmol/L. The patient reports stabilization of mood without adverse events. This scenario emphasizes dose adjustment in the setting of reduced renal function and the importance of age‑related considerations.
2. Scenario B: Lithium Toxicity Secondary to Diuretic Use
   A 42‑year‑old man on chronic lithium therapy (600 mg/day) develops mild nausea and tremor after initiating hydrochlorothiazide for hypertension. Serum lithium is measured at 1.2 mmol/L, exceeding the upper therapeutic limit. Lithium is temporarily discontinued, and the patient is instructed to hydrate. Serum levels normalize to 0.7 mmol/L after 48 hours. Lithium is re‑initiated at 300 mg/day, and careful monitoring ensues. This case illustrates the impact of drug interactions on lithium clearance and the necessity of timely dose adjustment.
3. Scenario C: Lithium in the Management of Mood Instability Post‑Stroke
   A 55‑year‑old woman with a recent ischemic stroke develops mood lability and subclinical mania. Lithium carbonate is started at 300 mg once daily, with serum lithium checked after 10 days. The level is 0.6 mmol/L, and the patient demonstrates improved affective stability. Given the concurrent use of antithrombotic therapy, renal function is closely monitored, and serum lithium is checked monthly. This example demonstrates lithium’s role in a complex clinical context involving neurologic and psychiatric comorbidities.

Problem‑Solving Approaches

• When serum lithium concentrations fall below the therapeutic range, evaluate the patient’s adherence, fluid intake, and dietary sodium. Consider increasing the dose or frequency, ensuring that renal function remains stable.
• In the presence of toxicity (e.g., tremor, ataxia, lethargy), immediately discontinue lithium and assess serum levels. If levels exceed 2.0 mmol/L, initiate dialysis or hemodialysis if indicated.
• For patients with chronic kidney disease, calculate a renally adjusted dose based on the estimated GFR, and incorporate a safety margin to account for inter‑individual variability.
• When introducing or discontinuing medications that influence renal handling of lithium (e.g., NSAIDs, ACE inhibitors), anticipate changes in serum concentration and adjust lithium dosing accordingly.
• Educate patients on the importance of maintaining consistent sodium intake and hydration, especially during periods of illness or changes in medication.

Summary/Key Points

• Lithium is a first‑line mood stabilizer with a well‑characterized therapeutic window of 0.6–1.0 mmol/L for acute mania and 0.4–0.8 mmol/L for maintenance.
• Its pharmacokinetics are dominated by renal excretion; therefore, serum levels are highly sensitive to changes in glomerular filtration rate, hydration status, dietary sodium, and concomitant medications.
• Key pharmacodynamic mechanisms include inhibition of phosphoinositide hydrolysis, suppression of GSK‑3β, modulation of cAMP signaling, and upregulation of BDNF, all of which converge to dampen neuronal hyperexcitability.
• Therapeutic drug monitoring is mandatory; serum lithium concentrations should be assessed after dose initiation, at steady state, and whenever clinical status or renal function changes.
• Clinical pearls: maintain consistent sodium intake, monitor renal and thyroid function, educate patients on signs of toxicity, and anticipate drug interactions that influence lithium clearance.

References

1. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.